Published in Obesity and Diabetes Week, August 15th, 2005
A phase IIb study evaluating CS-917 was halted earlier this year after two serious adverse events occurred during a phase I study that combined CS-917 with the diabetes drug metformin. After a comprehensive review of the program and the events and data surrounding these two events, Sankyo has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.